Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Drugs and Organics has submitted copies of its newspaper advertisement (published in Financial Express and Loksatta) containing the Un-Audited Financial Results for the quarter ended June 30, 2025, as required under SEBI LODR Regulation 47. The Board had approved these results on August 7, 2025. Standalone revenue from operations fell to Rs. 5,734.87 lakhs in Q1 FY26, down from Rs. 7,653.62 lakhs in Q1 FY25 and Rs. 7,303.86 lakhs in Q4 FY25. The company swung to a standalone net loss before tax of Rs. 898.35 lakhs in Q1 FY26, compared to a profit of Rs. 434.81 lakhs in Q1 FY25, with EPS turning negative at Rs. (8.67) versus Rs. 1.70 in the year-ago quarter. Consolidated results also showed a sharp decline, with revenue dropping to Rs. 36,739.53 lakhs and a loss of Rs. 8.72 per share for the quarter.
The results reveal a clear deterioration in Mangalam Drugs' quarterly performance, with revenue contracting and the company slipping into a loss versus a profit a year earlier. Shareholders should expect near-term pressure on sentiment, as the swing to negative EPS signals weak operating conditions in the latest quarter.